0KB2 Stock Overview
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Humanigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.013 |
| 52 Week High | US$0.02 |
| 52 Week Low | US$0.01 |
| Beta | -0.97 |
| 1 Month Change | 0% |
| 3 Month Change | 1.52% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KB2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | 2.5% |
| 1Y | n/a | -25.2% | 6.0% |
Return vs Industry: Insufficient data to determine how 0KB2 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 0KB2 performed against the German Market.
Price Volatility
| 0KB2 volatility | |
|---|---|
| 0KB2 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0KB2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0KB2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Cameron Durrant | www.humanigen.com |
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis.
Humanigen, Inc. Fundamentals Summary
| 0KB2 fundamental statistics | |
|---|---|
| Market cap | €549.02k |
| Earnings (TTM) | -€49.46m |
| Revenue (TTM) | €1.57m |
0.4x
P/S Ratio0.0x
P/E RatioIs 0KB2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KB2 income statement (TTM) | |
|---|---|
| Revenue | US$1.70m |
| Cost of Revenue | US$38.73m |
| Gross Profit | -US$37.03m |
| Other Expenses | US$16.61m |
| Earnings | -US$53.63m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | -2,179.40% |
| Net Profit Margin | -3,156.80% |
| Debt/Equity Ratio | 0% |
How did 0KB2 perform over the long term?
See historical performance and comparison